title: Effect of coadministration of M-CSF and IFN-alpha on NK1.1+ cells in mice.
abstract: The purpose of this study was to evaluate the effect of coadministration of macrophage colony-stimulating factor (M-CSF) and interferon-alpha (IFN-alpha) on NK1.1(+) cells in mice. Administration of M-CSF, but not IFN-alpha, increased the number of NK1.1(+) cells and CD11b(+) cells in spleen and blood. Coadministration of the two agents induced a greater increase in NK1.1(+) cells than did administration of M-CSF alone. Administration of M-CSF or IFN-alpha augmented the clearance activity of Yac-1 cells in lung, and coadministration of these agents further augmented this effect. The combination of M-CSF and IFN-alpha effectively reduced the formation of tumor nodules in lung and liver in an experimental metastasis model using B16 melanoma. The combination of M-CSF and IFN-alpha induced the increase and activation of NK1.1(+) cells more than either agent alone. These effects may contribute to the antimetastatic reaction by NK1.1(+) cells in vivo.
authors.affiliation: Biochemical Research Laboratory, Morinaga Milk Industry Co., Ltd., 5-Chome Higashihara Zama-city, Kanagawa pref., Japan. takuma-s@po.iijnet.or.jp
authors.forename: Takuma
authors.initials: T
authors.lastname: Sakurai
authors.forename: Eriko
authors.initials: E
authors.lastname: Misawa
authors.forename: Miyuki
authors.initials: M
authors.lastname: Tanaka-Douzono
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hagesita
authors.forename: Kouji
authors.initials: K
authors.lastname: Nomaguchi
authors.forename: Kuhara
authors.initials: K
authors.lastname: Tetsuya
authors.forename: Shinya
authors.initials: S
authors.lastname: Suzu
authors.forename: Muneo
authors.initials: M
authors.lastname: Yamada
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Hayasawa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Motoyoshi
mesh_terms: D000818:Animals; D039481:CD11b Antigen / Q000276:immunology; D039521:CD11c Antigen / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008213:Lymphocyte Activation; D016173:Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000556:secondary; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000627:therapeutic use; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology
chemical_list: D039481:CD11b Antigen; D039521:CD11c Antigen; D017252:CD3 Complex; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016173:Macrophage Colony-Stimulating Factor